Newark, NJ, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Sanjeev Luther, President and Chief Executive Officer of Rafael Pharmaceuticals, Inc. will be presenting at the BIO Investor Forum 2018 in San Francisco on Thursday, October 18. Rafael is a leader in the growing field of cancer metabolism-based therapeutics.
Mr. Luther will discuss the promising phase I/II trial results of Rafael’s lead metabolic cancer drug, CPI-613, and provide an overview of the Company’s Altered Metabolism Directed (AMD) drug platform. In addition, he will provide an update on the ongoing pivotal trials of CPI-613 in pancreatic cancer and acute myeloid leukemia (AML).
Interviews with Mr. Luther are available upon request.
WHERE: Westin St. Francis, San Francisco, CA; Presentation Room: Elizabethan D
WHEN: Thursday, October 18th, 2018; 10:45 AM
CONTACT: Jacob Jonas, 973-438-3176 or jacob.jonas@rafaelpharma.com
About Rafael Pharmaceuticals, Inc.
Rafael Pharmaceuticals, Inc. is a privately held clinical-stage, metabolic oncology therapeutics company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael’s primary objective is to develop innovative, highly selective, well tolerated and highly effective anti-cancer agents by selectively targeting altered metabolism in cancer cells. Rafael’s first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. CPI-613 has been granted orphan drug designation for the treatment of pancreatic cancer, acute myeloid leukemia (AML), peripheral T-cell lymphoma (PTCL), Burkitt lymphoma and myelodysplastic syndromes (MDS). The Company's investors include Rafael Holdings, Inc. (NYSE AMERICAN: RFL). For more information, visit http://www.rafaelpharma.com/.
Safe Harbor Statement
This press release contains forward-looking statements. These statements relate to future events or the company’s future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.
Contact
Sanjeev Luther
President & CEO Rafael Pharmaceuticals, Inc.
sanjeev.luther@rafaelpharma.com
Jacob Jonas
Public Relations, Rafael Pharmaceuticals, Inc.
jacob.jonas@rafaelpharma.com